Insight Molecular Diagnostics (IMDX) investor relations material

Executive summary

• Submitted GraftAssureDx to the FDA in March 2026, targeting kidney transplants first, with productive regulatory engagement and FDA authorization expected later in 2026.

• Early market access progress outside the U.S. with initial research-use kit sales in Switzerland and Southeast Asia, though immaterial to revenue.

• Strategic partnership with Bio-Rad to co-develop and commercialize transplant test kits, with first RUO kit sales in May 2025.

• Expansion into heart transplant testing underway, leveraging organ-agnostic technology and R&D investment.

• Six strategic goals for 2026 include U.S. and E.U. regulatory approvals, expanding research-use sales, and R&D for heart transplant applications.

Financial highlights

• Q1 2026 revenue was $32,000, all from laboratory services; Q2 2026 revenue projected at $250,000, mainly from laboratory services and minimal GraftAssureIQ sales.

• Net loss for Q1 2026 was $4.3 million, improved from $6.7 million in Q1 2025, mainly due to a $5.9 million gain from contingent consideration.

• Cash, cash equivalents, and restricted cash at March 31, 2026, totaled $29.4 million, bolstered by a $26 million direct offering in February 2026.

• Q2 cash burn expected above $9 million, with cash burn anticipated to decrease to ~$6 million per quarter in the second half of the year as R&D expenses decline.

• Research and development expenses rose 69% year-over-year to $5.0 million, reflecting increased investment in transplant product development.

Outlook and guidance

• Expectation of significant U.S. orders for GraftAssureIQ and GraftAssureDx following FDA marketing authorization later in 2026.

• Initial U.S. customers for GraftAssureIQ anticipated to place larger orders later this year.

• Long-term gross margin target of 70% or higher, but not expected in the first 6–12 months post-commercialization.

• Management expects continued operating losses and negative cash flows as investment in transplant and kitted product development continues.

• Sufficient cash is projected to meet operating requirements for at least the next twelve months following the report.